# Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

> **NCT01225562** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 21379 (actual)

## Conditions studied

- Myocardial Infarction
- Cardiovascular Death
- Atherothrombosis
- Stroke

## Interventions

- **DRUG:** Ticagrelor 90 mg
- **DRUG:** Ticagrelor 60 mg
- **DRUG:** Ticagrelor Placebo

## Key facts

- **NCT ID:** NCT01225562
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 21379 (ACTUAL)
- **Last updated:** 2016-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01225562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01225562, "Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01225562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*